Spyre Therapeutics (SYRE) Invested Capital (2016 - 2025)
Spyre Therapeutics (SYRE) has disclosed Invested Capital for 11 consecutive years, with $738.1 million as the latest value for Q4 2025.
- For the quarter ending Q4 2025, Invested Capital rose 35.95% year-over-year to $738.1 million, compared with a TTM value of $738.1 million through Dec 2025, up 35.95%, and an annual FY2025 reading of $738.1 million, up 35.95% over the prior year.
- Invested Capital was $738.1 million for Q4 2025 at Spyre Therapeutics, up from $466.1 million in the prior quarter.
- Across five years, Invested Capital topped out at $738.1 million in Q4 2025 and bottomed at -$237.9 million in Q3 2023.
- Average Invested Capital over 5 years is $215.1 million, with a median of $121.4 million recorded in 2021.
- The sharpest move saw Invested Capital plummeted 452.15% in 2023, then skyrocketed 977.07% in 2024.
- Year by year, Invested Capital stood at $83.9 million in 2021, then tumbled by 40.07% to $50.3 million in 2022, then surged by 268.56% to $185.4 million in 2023, then soared by 192.81% to $542.9 million in 2024, then surged by 35.95% to $738.1 million in 2025.
- Business Quant data shows Invested Capital for SYRE at $738.1 million in Q4 2025, $466.1 million in Q3 2025, and $515.7 million in Q2 2025.